Ginseng Ginger Echinacea Silybum Composition for Cancer Fatigue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer-related fatigue, a severe symptom affecting a significant percentage of cancer patients, particularly those undergoing chemotherapy and radiotherapy, is difficult to manage with existing palliative treatments due to their side effects and limited efficacy, and there is a need for a more effective and safer alternative.
Innovation Solution
A combination of Panax ginseng C.A. Mayer, Zingiber officinale, Echinacea angustifolia, and Silybum marianum extracts, standardized and formulated with specific excipients, is used to create a synergistic composition that addresses the multifactorial aspects of cancer-related fatigue, enhancing vitality, reducing pain and nausea, and improving quality of life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional palliative treatments (Cox-2 inhibitors, methylphenidate, steroids) are used to manage cancer-related fatigue, then alertness and attention may be improved, but major side effects and critical risk-benefit ratio worsen
Solution Approach 1:
The patent changes the chemical composition parameters by replacing synthetic drugs with a standardized plant extract combination containing specific compounds (ginsenosides, gingerols, echinacoside, silymarin) at defined concentrations, thereby maintaining therapeutic efficacy while reducing harmful side effects
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining four different plant extracts (Panax ginseng, Zingiber officinale, Echinacea angustifolia, Silybum marianum) where each component contributes specific beneficial properties while synergistically reducing the harmful effects associated with conventional single-agent treatments
2Reliability
If ginseng extracts are used to reduce fatigue, then immunostimulating and anticancer properties are improved, but preparation standardisation becomes problematic leading to erratic results
Solution Approach 1:
The patent establishes specific parameter ranges for active compounds (ginsenosides 2-10%, gingerols 1-5%, echinacoside 0.5-3%, silymarin 1-5%) and extraction conditions to ensure consistent composition and reproducible immunostimulating and anticancer effects across different preparations
Solution Approach 2:
The patent creates a multi-functional formulation where the plant extract combination simultaneously provides immunostimulating, anticancer, anti-fatigue, and hepatoprotective effects, making the preparation universally effective across multiple therapeutic indications while maintaining standardisation
3Reliability
If Silybum marianum extract is used to protect liver function, then cytoprotective action is improved, but absorption under altered gastrointestinal functionality becomes challenging
Solution Approach 1:
The patent optimizes the silymarin content parameter (1-5% in the combination) and combines it with phospholipids to enhance solubility and absorption, ensuring effective cytoprotective action even when gastrointestinal functionality is altered by cancer treatment
4Reliability
If Zingiber officinale is used to mitigate inflammatory state, then quality of life is improved, but anti-nausea action alone is insufficient for comprehensive symptom management
Solution Approach 1:
The patent creates a multi-functional formulation where Zingiber officinale provides both anti-inflammatory and anti-nausea effects, while the combination with other plant extracts adds immunostimulating, hepatoprotective, and anticancer properties, achieving comprehensive symptom management for cancer patients
Data Source
AI summary
Disclosed are compositions containing extracts of (a) Panax ginseng C.A. Mayer, (b) Zingiber officinale, (c) Echinacea angustifolia and (d) Silybum marianum or the phospholipid complex of silybin with phospholipids as active ingredients, mixed with suitable excipients.